News & Publications

Nov 08, 2023

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Aug 17, 2023

Foresight Diagnostics Strengthens Leadership Team with Addition of Chief Business Officer John Truesdell

Jun 13, 2023

Foresight Diagnostics Announces Study Demonstrating Prognostic Utility of PhasED-SeqTM for MRD Assessment after Frontline DLBCL Treatment at the 17th International Conference on Malignant Lymphoma

May 30, 2023

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

icon-download Download Paper

Apr 27, 2023

Foresight Diagnostics' approach for the earlier detection of cancer recurrence pulls in nearly $59M

Apr 27, 2023

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Apr 20, 2023

Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq

icon-download Download Poster

Apr 04, 2023

Ultrasensitive Detection of Circulating Tumor DNA In Untreated Diffuse Large B-cell Lymphoma

icon-download Download Poster

Apr 04, 2023

Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference

Mar 09, 2023

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

Mar 09, 2023

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mar 09, 2023

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Dec 19, 2022

Data supporting the routine use of PhasED-Seq® for MRD analysis in DLBCL featured in Precision Oncology News

Nov 29, 2022

Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies from their Patented PhasED-Seq®MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

Sep 27, 2022

Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology  

Jun 22, 2022

Foresight Diagnostics featured as part of Colorado’s growing healthcare innovation community

Jun 04, 2022

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

icon-download Download Poster

May 02, 2022

Jake Chabon Ph.D., Co-founder/CEO of Foresight Diagnostics joins the Berkeley Center for Law & Technology (BCLT) Expert Series podcast

Apr 26, 2022

Foresight Diagnostics Expands Scientific Advisory Board with Appointment of Christopher R. Flowers, M.D., M.S.

Apr 06, 2022

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-cell Lymphoma

icon-download Download Poster

Apr 03, 2022

Foresight Diagnostics Announces the Hiring of Sandra Close, Ph.D., as Chief Operations Officer

Apr 01, 2022

Inferring gene expression from cell-free DNA fragmentation profiles

Mar 29, 2022

Nature Biopharma Dealmakers: Closing the gap on minimal residual disease detection in cancer

icon-download Download Paper

Jan 19, 2022

Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.

Dec 13, 2021

Foresight Diagnostics' PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas

Dec 13, 2021

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Dec 13, 2021

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Dec 13, 2021

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Dec 13, 2021

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Oct 12, 2021

Lightning does strike twice: leveraging phased variants to enhance minimal residual disease detection

icon-download Download Review Paper

Sep 20, 2021

What’s Next for Liquid Biopsy Tests?

Jul 26, 2021

Foresight Diagnostics Commercializing PhasED-seq Liquid Biopsy Tech for Improved MRD Detection

Jul 22, 2021

Foresight Diagnostics’ PhasED-Seq detects circulating tumor DNA at extremely low levels

Jul 22, 2021

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Jul 22, 2021

Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas

Jun 17, 2021

Foresight Diagnostics to Present a Vision of the New Standard of Lymphoma MRD Detection at the 16th International Conference on Malignant Lymphoma

Jun 03, 2021

Leveraging Phased Variants for Personalized Minimal Residual Disease Detection in Localized Non-Small Cell Lung Cancer

icon-download Download poster

Jun 03, 2021

Foresight Diagnostics to Present Clinical Data of Industry-Leading Minimal Residual Disease (MRD) Technology in Lymphoma and Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 03, 2021

Phased variants improve DLBCL minimal residual disease detection at the end of therapy

icon-download Download poster

Jun 02, 2021

Foresight Diagnostics Completes Series A Financing to Accelerate Development of its Industry-Leading Minimal Residual Disease (MRD) Technology

Mar 25, 2020

Integrating genomic features for non-invasive early lung cancer detection

Nov 13, 2019

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Jul 25, 2019

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
 
2023-11-28 11:33